Prostanoids are established mediators of inflammation, and the therapeutic efficacy of drugs that block their global biosynthesis in conditions such as rheumatoid arthritis is well-known.

AGN 225660 blocks pro-inflammatory prostanoid receptors (DP1, EP1, EP4, FP, TP). AGN 225660 represents a second-generation compound with an “druggable” core structure.

AGN 225660 exhibited good ocular bioavailability and was active in reducing ocular inflammation associated with phacoemulsification surgery, lipopolysaccharide (LPS), and arachidonic acid induced uveitis.

Ocular Pharmacokinetic studies were performed at Medicilon.

Reference:

David F Woodward, et al. A Second Generation Prostanoid Receptor Antagonist Acting at Multiple Receptor Subtypes. ACS Pharmacol Transl Sci . 2020 Oct 26;3(6):1199-1210. doi: 10.1021/acsptsci.0c00118.